Clinical Efficacy and Safety Profile of Suzetrigine: A Novel Non-opioid Analgesic Targeting NaV1.8 Sodium Channel.

Pain management remains a significant clinical challenge due to the safety concerns and addiction risks associated with conventional therapies. The development of selective NaV1.8 sodium channel inhibitors offers a promising non-opioid alternative. This review evaluates the clinical pharmacology, clinical efficacy, and safety profile of suzetrigine (VX-548), a novel selective NaV1.8 inhibitor for treating moderate to severe acute pain. A systematic literature search of major academic databases, clinical trial registries, and regulatory documents was conducted to gather relevant data published between 2020 and 2025. Suzetrigine exhibits high selectivity for the NaV1.8 channel through a novel allosteric mechanism with significant pain relief compared to placebo and comparable efficacy to a standard hydrocodone/acetaminophen combination. The drug displayed a favorable safety profile with a lower incidence of common opioid-related adverse effects, such as nausea and dizziness, and showed no evidence of abuse potential in clinical and preclinical assessments. Suzetrigine represents a significant advancement in acute pain management as a first-in-class selective NaV1.8 inhibitor. Its recent approval by the U.S. Food and Drug Administration for moderate to severe acute pain underscores its potential as an effective non-opioid therapeutic. While its short-term efficacy and safety are well established, future research should focus on its long-term safety profile and its utility across a broader range of pain conditions.